Prevention of incident SARS-CoV-2 infection through combined intranasal and intradermal administration of the GLS-5310 DNA vaccine during the Omicron outbreak
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
We evaluated the safety and immunogenicity of boost vaccination with the GLS-5310 SARS-CoV-2 DNA vaccine to those previously vaccinated with the Ad26.S.CoV2, BNT162b2, or mRNA-1273 vaccines. GLS-5310 was administered intradermally (ID) and followed by application of suction using the GeneDerm device, or ID as well as intranasally (IN) by nasal atomizer. GLS-5310 vaccination was well tolerated. With respect to primary vaccine type, boost vaccination induced a 1.5- to 4-fold increase in antibody titers, up to a 14.4-fold increase in T cell responses by ELISpot. Incident SARS-CoV-2 infections, during a period of Omicron prevalence, were reported for 24.2% of participants: 1 of 17 (5.9%) vaccinated ID plus IN versus 16 of 53 (30.2%) vaccinated ID only, p = 0.042 (chi-square analysis). This first ever trial of a DNA vaccine administered IN plus ID showed potential protection against incident SARS-CoV-2 Omicron infection. NCT Clinical Trial number: NCT05182567
